PL372921A1 - Stabilizowany preparat naturalnego kanabinoidu - Google Patents

Stabilizowany preparat naturalnego kanabinoidu

Info

Publication number
PL372921A1
PL372921A1 PL03372921A PL37292103A PL372921A1 PL 372921 A1 PL372921 A1 PL 372921A1 PL 03372921 A PL03372921 A PL 03372921A PL 37292103 A PL37292103 A PL 37292103A PL 372921 A1 PL372921 A1 PL 372921A1
Authority
PL
Poland
Prior art keywords
sugar
natural cannabinoid
mixture
glass
drying
Prior art date
Application number
PL03372921A
Other languages
English (en)
Other versions
PL209134B1 (pl
Inventor
Anko C. Eissens
Drooge Dirk J. Van
Wouter L.J. Hinrichs
Henderik W. Frijlink
Original Assignee
Solvay Pharmaceuticals B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals B.V. filed Critical Solvay Pharmaceuticals B.V.
Publication of PL372921A1 publication Critical patent/PL372921A1/pl
Publication of PL209134B1 publication Critical patent/PL209134B1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL372921A 2002-04-03 2003-04-02 Sposób wytwarzania kompozycji farmaceutycznej zawierającej naturalny związek kanabinoidowy i kompozycja farmaceutyczna otrzymywana tym sposobem PL209134B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36961302P 2002-04-03 2002-04-03
EP02076339 2002-04-04

Publications (2)

Publication Number Publication Date
PL372921A1 true PL372921A1 (pl) 2005-08-08
PL209134B1 PL209134B1 (pl) 2011-07-29

Family

ID=28676390

Family Applications (1)

Application Number Title Priority Date Filing Date
PL372921A PL209134B1 (pl) 2002-04-03 2003-04-02 Sposób wytwarzania kompozycji farmaceutycznej zawierającej naturalny związek kanabinoidowy i kompozycja farmaceutyczna otrzymywana tym sposobem

Country Status (16)

Country Link
EP (1) EP1492503B1 (pl)
JP (1) JP4491241B2 (pl)
CN (1) CN100592903C (pl)
AT (1) ATE413862T1 (pl)
AU (1) AU2003240759B2 (pl)
BR (1) BR0308779A (pl)
CA (1) CA2480270A1 (pl)
DE (1) DE60324668D1 (pl)
DK (1) DK1492503T3 (pl)
ES (1) ES2316759T3 (pl)
HR (1) HRP20040816A2 (pl)
MX (1) MXPA04009673A (pl)
NO (1) NO20044749L (pl)
PL (1) PL209134B1 (pl)
RU (1) RU2311178C2 (pl)
WO (1) WO2003082246A1 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1428526A1 (en) * 2002-12-13 2004-06-16 Rijksuniversiteit Groningen Formulation for fast dissolution of lipophilic compounds
DE10339197A1 (de) * 2003-08-22 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Sprühgetrocknete amorphe Pulver mit geringer Restfeuchte und guter Lagerstabilität
TW200621310A (en) * 2004-11-10 2006-07-01 Univ Groningen A process for preparing formulations of lypophilic active substances by spray freeze drying
GB0523638D0 (en) * 2005-11-21 2005-12-28 Cambridge Biostability Ltd Pharmaceutical device for the administration of substances to patients
JO3112B1 (ar) 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
BR112012024432A2 (pt) 2010-03-29 2016-05-31 Ferring Bv composição farmacêutica de dissolução rápida
JP6174585B2 (ja) 2011-09-16 2017-08-02 フェリング ベスローテン フェンノートシャップ 速溶性医薬組成物
US8741341B2 (en) * 2012-05-07 2014-06-03 Insys Therapeutics, Inc. Manufacturing and packaging room temperature stable dronabinol capsules
US11833118B2 (en) 2016-01-20 2023-12-05 Flurry Powders, Llc Encapsulation of lipophilic ingredients in dispersible spray dried powders suitable for inhalation
JP6953414B2 (ja) * 2016-01-20 2021-10-27 フラリー パウダーズ エルエルシーＦｌｕｒｒｙ Ｐｏｗｄｅｒｓ，Ｌｌｃ 親油性成分を含む吸入に好適な分散性の噴霧乾燥粉末を製造する方法
WO2019211772A1 (en) * 2018-05-03 2019-11-07 Radient Technologies Inc. Obtaining extracts in a solid form
CA3106476A1 (en) * 2018-07-10 2020-01-16 Cardinal Advisory Limited Formulation of cannabinoid compounds
CN110200953B (zh) * 2019-06-15 2022-02-08 汉义生物科技（北京）有限公司 大麻素在制备吸入给药药物中的应用
CA3128696C (en) * 2020-08-21 2023-09-26 Organigram Inc. Buccal dosage forms comprising oligosaccharides
WO2023224960A1 (en) * 2022-05-17 2023-11-23 Orcosa Inc. Rapidly infusing cannabinoid compositions, processes of manufacture, and methods of use
WO2023250274A1 (en) 2022-06-22 2023-12-28 Ilera Therapeutics Llc Enhanced capture and dissolution matrix for cannabinoids and methods of making the same

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8903593D0 (en) * 1989-02-16 1989-04-05 Pafra Ltd Storage of materials
GB9010742D0 (en) * 1990-05-14 1990-07-04 Quadrant Bioresources Ltd Stabilization of biological macromolecular substances
US5955448A (en) * 1994-08-19 1999-09-21 Quadrant Holdings Cambridge Limited Method for stabilization of biological substances during drying and subsequent storage and compositions thereof
IL117773A (en) * 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
GB9726916D0 (en) * 1997-12-19 1998-02-18 Danbiosyst Uk Nasal formulation
US6509005B1 (en) * 1998-10-27 2003-01-21 Virginia Commonwealth University Δ9 Tetrahydrocannabinol (Δ9 THC) solution metered dose inhaler
NL1012300C2 (nl) * 1999-06-11 2000-12-12 Rijksuniversiteit Stabilisator voor farmaca.

Also Published As

Publication number Publication date
CA2480270A1 (en) 2003-10-09
CN1642527A (zh) 2005-07-20
NO20044749L (no) 2005-01-03
BR0308779A (pt) 2004-12-28
RU2311178C2 (ru) 2007-11-27
HK1078458A1 (zh) 2006-03-17
DE60324668D1 (de) 2008-12-24
PL209134B1 (pl) 2011-07-29
JP2005521710A (ja) 2005-07-21
DK1492503T3 (da) 2009-03-09
WO2003082246A1 (en) 2003-10-09
JP4491241B2 (ja) 2010-06-30
EP1492503B1 (en) 2008-11-12
ATE413862T1 (de) 2008-11-15
AU2003240759B2 (en) 2008-02-14
CN100592903C (zh) 2010-03-03
EP1492503A1 (en) 2005-01-05
ES2316759T3 (es) 2009-04-16
MXPA04009673A (es) 2005-01-11
AU2003240759A1 (en) 2003-10-13
HRP20040816A2 (en) 2005-06-30
RU2004132190A (ru) 2005-04-20

Similar Documents

Publication Publication Date Title
ATE413862T1 (de) Stabilisierte natürliche cannabinoid formulierung
AU2003285820A1 (en) Formulation for fast dissolution of lipophilic compounds
EP1461347B8 (en) 2-o-(beta-d-glucopyranosyl)ascorbic acid, process for its production, and foods and cosmetics containing compositions comprising it
WO2003045411A3 (de) Ingwer-extraktzubereitung
DE60012783D1 (de) Stabile, durch sprühtrocknung in einen kohlenhydratsubstrat hergestellte zubereitung und verfahren zu deren herstellung
WO1996033744A3 (en) Compositions in glassy phase, stabilised by a sugar
WO2002067969A3 (en) Stabilized insulin formulations
BR0212960A (pt) composição de tabaco mastìgavel e/ou inalável, processo para preparar a mesma, e, substrato
EP3962963A1 (en) METHODS FOR FORMING INCLUSION COMPLEXES WITH HYDROPHILIC ß-CYCLODEXTRIN DERIVATIVES AND COMPOSITIONS THEREOF
WO2009107983A3 (ko) 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물
DE502004006512D1 (de) Sprühgetrocknete amorphe pulver mit geringer restfeuchte und guter lagerstabilität
EP1166792A3 (en) Extracts, compounds & pharmaceutical compositions having anti-diabetic activity and their use
EP1167435A3 (en) Inclusion compounds of vanillyl alcohol derivative in cyclodextrin and compositions containing the same
WO2002047492A3 (en) A moisture and oxygen stable composition and a process for obtaining said composition
WO2005025500A3 (en) Process for preparing water soluble diterpenes and their applications
TW200621310A (en) A process for preparing formulations of lypophilic active substances by spray freeze drying
WO2002096373A3 (en) Topical cosmetic composition comprising an alpha-beta-unsaturated ester as bonding agent
WO2005048985A3 (en) Alpha 1-antitrypsin compositions and treatment methods using such compositions
WO2002096372A3 (en) Topical composition comprising an activated, trans-structured cosmetic bonding agent
WO2004073652A3 (en) Powder formulations of recombinant staphylococcal enterotoxin b (rseb) made by atmospheric spray-freeze drying for improved vaccination
CA2119548A1 (en) Odorant compositions
WO2002072058A3 (en) Topical composition comprising a functionalized acid anhydride-based cosmetic bonding agent
WO2002072060A3 (en) Topical composition comprising a three membered cyclic compound-based cosmetic bonding agent
WO2002072056A3 (en) Topical composition comprising a diazonium salt-based cosmetic bonding agent
WO2002072055A3 (en) Topical composition comprising a cyclic imidocarbonate-based cosmetic bonding agent

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20130402